
Harm Reduction Group Q2 2023 - Clouds gather on Norway's vaping horizon

Redeye trims its valuation range after reviewing Harm Reduction Group's Q2 2023 report. Weak B2C sales for the quarter and concerns about a potential flavour ban in Norway's vaping market contribute to a lowered valuation.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Harm Reduction Group Q2 2023 - Clouds gather on Norway's vaping horizon](#)